| Literature DB >> 30822325 |
Yongseok Mun1, Mee Kum Kim1,2, Joo Youn Oh1,2.
Abstract
PURPOSE: To investigate the risk factors, microbiological profiles, antibiotic susceptibility patterns, and treatment outcome in patients with bacterial keratitis at a Korean tertiary hospital.Entities:
Mesh:
Year: 2019 PMID: 30822325 PMCID: PMC6396910 DOI: 10.1371/journal.pone.0213103
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographics and clinical characteristics of patients with bacterial keratitis.
| Total | 2007–2011 | 2012–2016 | ||
|---|---|---|---|---|
| Number of eyes (%) | 101 | 39 (38.6%) | 62 (61.4%) | |
| Age (years) | 57.4 ± 19.9 | 53.4 ± 22.2 | 59.9 ± 18.2 | 0.110 |
| Sex (male:female) | 52:49 | 23:16 | 29:33 | 0.232 |
| Diabetes mellitus | 17 (16.8%) | 10 (25.6%) | 7 (11.3%) | 0.061 |
| Immune-compromised status (SJS, etc.) | 12 (11.9%) | 4 (10.3%) | 8 (12.9%) | 0.762 |
| Contact lens wear | 12 (11.9%) | 4 (10.3%) | 8 (12.9%) | 0.762 |
| Topical anti-glaucoma medication | 29 (28.7%) | 11 (28.2%) | 18 (29.0%) | 0.929 |
| Topical corticosteroids | 39 (38.6%) | 22 (56.4%) | 17 (27.4%) | 0.004 |
| Ocular surgery history | 60 (59.4%) | 24 (61.5%) | 36 (58.1%) | 0.729 |
| PK | 30 (29.7%) | 16 (41.0%) | 14 (22.6%) | |
| Ocular trauma history | 8 (7.9%) | 2 (5.1%) | 6 (9.7%) | 0.480 |
PK: penetrating keratoplasty, SJS: Stevens-Johnson syndrome
Identification of bacteria isolated from cultures of corneal scraping.
| Total | 2007–2011 | 2012–2016 | |
|---|---|---|---|
| 107 | 42 | 65 | |
| 60 (56.1%) | 26 (61.90%) | 34 (52.3%) | |
| Coagulase-negative staphylococci (CNS) | 17 (15.9%) | 10(23.8%) | 7 (10.8%) |
| | 9 | 6 | 3 |
| | 1 | 0 | 1 |
| | 1 | 1 | 0 |
| | 1 | 1 | 0 |
| | 1 | 0 | 1 |
| | 1 | 1 | 0 |
| | 2 | 1 | 1 |
| CNS, unspecified | 1 | 0 | 1 |
| 13 (12.1%) | 7 (16.7%) | 6 (9.2%) | |
| 9 (8.4%) | 4 (9.5%) | 5 (7.7%) | |
| Viridans group streptococci | 6 (5.6%) | 3 (7.1%) | 3 (4.6%) |
| 3 (2.8%) | 0 (0%) | 3 (4.6%) | |
| 2 (1.9%) | 0 (0%) | 2 (3.1%) | |
| 1 (0.9%) | 0 (0%) | 1 (1.5%) | |
| 1 (0.9%) | 0 (0%) | 1 (1.5%) | |
| 1 (0.9%) | 1 (2.4%) | 0 (0%) | |
| 1 (0.9%) | 0 (0%) | 1 (1.5%) | |
| 1 (0.9%) | 0 (0%) | 1 (1.5%) | |
| 4 (3.7%) | 1 (2.4%) | 3 (4.6%) | |
| 1 (0.9%) | 0 (0%) | 1 (1.5%) | |
| 9 (8.4%) | 2 (4.8%) | 7 (10.8%) | |
| | 6 (5.6%) | 2 (4.8%) | 4 (6.2%) |
| | 2 (1.9%) | 0 (0%) | 2 (3.1%) |
| | 1 (0.9%) | 0 (0%) | 1 (1.5%) |
| 3 (2.8%) | 2 (4.8%) | 1 (1.5%) | |
| | 2 (1.9%) | 1 (2.4%) | 1 (1.5%) |
| | 1 (0.9%) | 1 (2.4%) | 0 (0%) |
| 35 (32.7%) | 12 (28.6%) | 23 (35.4%) | |
| | 11 (10.3%) | 4 (9.5%) | 7(10.8%) |
| | 5 (4.7%) | 1 (2.4%) | 4 (6.2%) |
| | 4 (3.7%) | 3 (7.1%) | 1 (1.5%) |
| | 2 (1.9%) | 0 (0%) | 2 (3.1%) |
| | 1 (0.9%) | 0 (0%) | 1 (1.5%) |
| | 1 (0.9%) | 0 (0%) | 1 (1.5%) |
| | 1 (0.9%) | 1 (2.4%) | 0 (0%) |
| | 1 (0.9%) | 0 (0%) | 1 (1.5%) |
| | 1 (0.9%) | 1 (2.4%) | 0 (0%) |
| | 1 (0.9%) | 0 (0%) | 1 (1.5%) |
| | 1 (0.9%) | 0 (0%) | 1 (1.5%) |
| | 1 (0.9%) | 0 (0%) | 1 (1.5%) |
| | 1 (0.9%) | 1 (2.4%) | 0 (0%) |
| | 1 (0.9%) | 0 (0%) | 1 (1.5%) |
| | 1 (0.9%) | 0 (0%) | 1 (1.5%) |
| | 1 (0.9%) | 0 (0%) | 1 (1.5%) |
| | 1 (0.9%) | 1 (2.4%) | 0 (0%) |
Antibiotic susceptibility of isolated bacteria.
Number of eyes (%).
| Gram-positive | Gram-negative | |||||
|---|---|---|---|---|---|---|
| Total | 2007–2011 | 2012–2016 | Total | 2007–2011 | 2012–2016 | |
| Vancomycin | 67/67 (100%) | 28/28 (100%) | 39/39 (100%) | 1/1 (100%) | N/A | 1/1 (100%) |
| Cefazolin | 7/13 (53.8%) | 7/13 (53.8%) | N/A | 1/4 (25.0%) | 1/4 (25.0%) | N/A |
| Cefuroxime | 8/18 (44.4%) | 7/14 (50.0%) | 1/4 (25.0%) | 3/6 (50.0%) | 2/5 (40.0%) | 1/1 (100%) |
| Chloramphenicol | 37/43 (86.0%) | 17/20 (85%) | 20/23 (87.0%) | 2/2 (100%) | 1/1 (100%) | 1/1 (100%) |
| Oxacillin | 16/30 (53.3%) | 10/18 (55.5%) | 6/12 (50.0%) | N/A | N/A | N/A |
| Penicillin | 9/41 (22.0%) | 2/21 (9.5%) | 7/20 (35%) | N/A | N/A | N/A |
| Ciprofloxacin | 26/29 (89.7%) | 14/16 (87.5%) | 12/13 (92.3%) | 31/34 (91.2%) | 13/14 (92.9%) | 18/20 (90.0%) |
| Levofloxacin | 23/24 (95.8%) | 5/5 (100%) | 18/19 (94.7%) | 8/8 (100%) | 8/8 (100%) | N/A |
| Moxifloxacin | 15/16 (93.8%) | 4/4 (100%) | 11/12 (91.7%) | N/A | N/A | N/A |
| Meropenem | 9/16 (56.3%) | 8/14 (57.1%) | 1/2 (50.0%) | 31/31 (100%) | 11/11 (100%) | 20/20 (100%) |
| Imipenem | 14/28 (50.0%) | 8/16 (50.0%) | 6/12 (50.0%) | 36/36 (100%) | 14/14 (100%) | 22/22 (100%) |
| Tobramycin | 1/1 (100%) | 1/1 (100%) | N/A | 29/30 (96.7%) | 13/13 (100%) | 16/17 (94.1%) |
| Ceftazidime | N/A | N/A | N/A | 34/34 (100%) | 13/13 (100%) | 21/21 (100%) |
| Amikacin | 0/1 (0) | N/A | 0/1 (0) | 35/36 (97.2%) | 13/13 (100%) | 22/23 (95.7%) |
| Gentamicin | 19/28 (67.9%) | 10/16 (62.5%) | 9/12 (75.0%) | 23/26 (88.5%) | 10/10 (100%) | 13/16 (81.3%) |
N/A: not available
Visual outcome after treatment.
Number of eyes (%).
| Visual acuity | Gram-positive | Gram-negative | Total | |
|---|---|---|---|---|
| Improved | 31 (50.8%) | 14 (41.2%) | 45 (47.4%) | 0.623 |
| No change | 18 (29.5%) | 13 (38.2%) | 31 (32.6%) | |
| Worsened | 12 (19.7%) | 7 (20.6%) | 19 (20.0%) | |
| Total | 61 | 34 | 95 |
Risk factors associated with evisceration.
Number of eyes (%).
| Evisceration | No evisceration | ||
|---|---|---|---|
| Number of eyes | 8 | 93 | |
| Age (years) | 56.6 ± 20.4 | 66.1 ± 12.1 | 0.204 |
| Immunocompromised disease (diabetes mellitus, SJS, etc.) | 3 (37.5%) | 26 (27.9%) | 0.686 |
| Topical glaucoma medication | 6 (75.0%) | 23 (24.7%) | 0.006 |
| Topical corticosteroids | 5 (62.5%) | 34 (36.6%) | 0.255 |
| History of ocular surgery | 8 (100%) | 52 (55.9%) | 0.019 |
| History of ocular trauma | 2 (25.0%) | 6 (6.5%) | 0.121 |
| Gram (+) / Gram (-) | 3 / 5 | 63 / 30 | 0.121 |
SJS: Stevens-Johnson syndrome